Jove
Visualize
联系我们

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease.

Brain communications·2026
Same author

Biomarkers in Alzheimer's disease clinical trials: 2025.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trials.

The journal of prevention of Alzheimer's disease·2025
Same author

Harnessing combination therapy: Current treatments, recent advancements, and future directions in Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2025
Same author

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.

Alzheimer's & dementia (New York, N. Y.)·2024
Same author

Racial and ethnic differences in disease course Medicare expenditures for beneficiaries with dementia.

Journal of the American Geriatrics Society·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Howard M Fillit1

  • 1Alzheimer's Drug Discovery Foundation, New York, NY, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

开发针对陶氏病理的血液测试对于阿尔茨海默病 (AD) 护理至关重要. 这些测试将使精确的患者分层和个性化治疗成为可能,改善超越目前基于粉样蛋白的诊断结果.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物发现发现
  • 精准医学是一门精准的医学.

背景情况:

  • 根据tau负担对阿尔茨海默氏症 (AD) 患者进行分层对研究和临床护理至关重要.
  • 病理与患者的结果有很强的相关性,正如LEQ和DONA等研究所显示的那样.
  • 目前的血液生物标志物主要检测粉样蛋白病理,限制了全面的AD评估.

研究的目的:

  • 突出需要具有成本效益的,非侵入性的血液检测,以检测病理,而不依赖于粉样蛋白.
  • 强调生物标志物对于预测疾病进展和指导治疗干预的重要性.
  • 倡导使用粉样蛋白和蛋白生物标志物进行个性化AD护理的患者分层.

主要方法:

  • 对临床试验数据 (LEQ,DONA) 的审查,将tau病理与患者结果相关联.
  • 对现有的成像和脑脊液 (CSF) 研究对在AD中的作用的分析.
  • 讨论基于血液的粉样蛋白生物标记物的当前限制 (例如,血粉样蛋白-β比率).

主要成果:

  • 陶氏病理是阿尔茨海默氏症患者结果和疾病进展的关键预测因素.
  • 现有的血液检测主要集中在粉样蛋白上,未能捕捉的贡献.
  • 开发独立的血测试对于全面的AD评估至关重要.

结论:

  • 将生物标志物纳入临床实践将使精确的患者分层和个性化治疗策略成为可能.
  • 根据个体的粉样蛋白和蛋白样本来定制治疗,可以优化疗效并减缓疾病的进展.
  • 阿尔茨海默病护理的发展取决于开发先进的生物标志物,包括tau,用于精准医学和下一代疗法.